Bloomberg News

Temasek Boosted Stake in U.S. Health-Care Industry Last Quarter

May 15, 2014

Temasek Holdings Pte, Singapore’s state-owned investment firm, purchased stocks in Thermo Fisher Scientific Inc. (TMO:US) and BioMarin Pharmaceutical Inc. (BMRN:US) in the first quarter as it boosted its stake in the U.S. health-care industry.

Temasek, directly or through its units, bought 5.3 million shares valued at $634 million in Thermo Fisher, a manufacturer of scientific instruments and chemicals, according to a filing yesterday with the U.S. Securities and Exchange Commission. It purchased 1.6 million shares valued at $106 million in BioMarin Pharmaceutical, a developer of therapeutic enzyme products. The investment firm also almost doubled its stake in biopharmaceutical company Gilead Sciences Inc. (GILD:US) to 12.6 million shares, according to the filing.

The transactions came as Temasek in March agreed to buy a 25 percent stake in Hutchison Whampoa (13) Ltd.’s retail arm A.S. Watson & Co., which owns health and beauty stores, for HK$44 billion ($5.7 billion). The health-care industry is expected to expand as people live longer and the growing middle class in emerging markets can afford better treatment. Life expectancy around the world surged in the past two decades as the rate of child mortality declined in Africa and wealthier countries improved monitoring and treatment of chronic diseases, according to a study by the World Health Organization.

“State investors recently increased their exposure to the health-care sector, mainly in developed countries,” said Enrico Soddu, an analyst at the London-based Institutional Investor’s Sovereign Wealth Center. “We might see more of that in the coming months.”

Stephen Forshaw, a spokesman for Temasek, confirmed the filing.

“The changes in holdings of various companies are part of the ongoing cycle of rebalancing the portfolio,” Forshaw said. “Some adjustments occur where we have an opportunity to invest in companies consistent with our investment themes.”

Acquiring stakes in “companies with distinctive intellectual property and other competitive advantages” is one of the investment themes of Temasek, according to its website.

Temasek, wholly owned by Singapore’s Ministry of Finance, is the ninth-biggest state investor with an estimated $173 billion of assets, according to the website of the Sovereign Wealth Center. The world’s biggest is Norway’s Government Pension Fund Global, while Singapore’s other sovereign investor GIC Pte ranks fifth, according to the center’s estimates.

Money managers who oversee more than $100 million in equities must file a Form 13F with the SEC within 45 days of each quarter’s end to show their U.S.-listed stocks, options and convertible bonds. The filings don’t show non-U.S. securities or how much cash the firms hold.

To contact the reporter on this story: Klaus Wille in Singapore at kwille@bloomberg.net

To contact the editors responsible for this story: Andreea Papuc at apapuc1@bloomberg.net Mary Romano, Pierre Paulden


Best LBO Ever
LIMITED-TIME OFFER SUBSCRIBE NOW

Companies Mentioned

  • TMO
    (Thermo Fisher Scientific Inc)
    • $124.12 USD
    • 0.52
    • 0.42%
  • BMRN
    (BioMarin Pharmaceutical Inc)
    • $69.38 USD
    • 1.17
    • 1.69%
Market data is delayed at least 15 minutes.
 
blog comments powered by Disqus